Biodegradable Medical Polymer Market

Key data points: Market size in 2027 = $4 billion and 2035 = $13 billion, growth forecast = 16.9% annually for the next 8 years. Scroll below to get more insights. This market report covers trends, opportunities and forecasts in biodegradable medical polymer market to 2035 by material type (ceramic matrix composites, oxide ceramics, non-oxide ceramics, and advanced porous ceramics), product form (powder, tiles, coatings, fibers, and bulk), application (drug delivery, implants, sutures, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World) Biodegradable Medical Polymer Market The future of the global biodegradable medical polymer market looks promising with opportunities in the drug delivery, implant, and suture markets. The global biodegradable medical polymer market is expected to reach an estimated $13 billion by 2035 from $4 billion in 2027 with a CAGR of 16.9% from 2027 to 2035. The major drivers for this market are the growing preference for minimally invasive surgical procedures, the rising demand for advanced drug delivery systems, and the increasing adoption of bioresorbable medical implants. • Lucintel forecasts that, within the material type category, ceramic matrix composite is expected to witness higher growth over the forecast period due to the superior thermal stability and mechanical strength for advanced applications. • Within the application category, drug delivery is expected to witness the highest growth over the forecast period due to the increasing adoption of controlled and targeted drug delivery. • In terms of regions, North America will remain the largest region over the forecast period due to the strong nanotechnology research and expanding pharmaceutical manufacturing capabilities. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below. Emerging Trends in Biodegradable Medical Polymer Market During 2024-27, biodegradable polymers moved beyond sutures and drug coatings into structural cardiovascular scaffolds and 3D printed personalized implants. Lucintel reports that this innovation will impact the polymer chemistries and manufacturing technologies that will win device maker preference. • 3D Printed Personalized Scaffolds: In the field of 3D printed devices, additive manufacturing has enabled patient specific design of bioresorbable scaffolds, and 3D printing is the primary enabler of bioresorbable vascular scaffolds. The growth of personalized medicine will continue to drive the shift from off-the-shelf to customized 3D printed polymer scaffolds across cardiovascular and orthopedic applications. • Polylactide’s Dominance in Absorbable Implants: Polylactic acid (PLA) dominates the biodegradable polymer market in 2026 with a 35% share, driven by broad medical device applications across sutures, orthopedic pins and scaffolds. The growth in absorbable implants will create further demand for PLA, and retain its dominant share due to its safety record and broad device processor preference. • Integration of Drug Delivery Systems: Bioresorbable polymers designed for controlled release of drugs are gaining significant share of the market with drug delivery systems projected to comprise some 30% of total applications in 2026 due to the continuously increasing demand for controlled release therapeutics. Pharmacists’ growing preference for localized, controlled release drug formulations will enhance the scope of these polymer formulations beyond cardiovascular and orthopedic applications. • Regional Manufacturing Diversification: Those countries that previously relied on imported biodegradable polymer feedstock now are producing biodegradable polymers domestically. India is projected to have the fastest growing bioresorbable polymer manufacture at a 19.1% CAGR until 2036. As countries work on building supply chain resilience, this manufacturing diversification will keep shifting the location of manufacture for medical grade biodegradable polymers. • Permanent Implant Replacement: Biodegradable materials are being preferred by the healthcare community over permanent metallic or synthetic implants. By 2026, the healthcare sector is anticipated to comprise around 45% of the total biodegradable polymer demand. With the focus being placed on reducing the need for secondary surgical removals, absorbable materials will displace permanent implants across a broader scope of clinical applications. It's apparent that over the coming years, medical polymers that are biodegradable will have an even larger impact and will displace permanent implants in new, diverse regions that previously never relied on biodegradable implants. Recent Developments in the Biodegradable Medical Polymer Market Consolidation and distribution agreements for biodegradable medical polymers will continue to grow 2024 to 2026, as compounders and materials suppliers look to secure specialized manufacturing capacity and widen their market share. According to Lucintel, these market trends break with the traditional fragmented, one-company supply model for the sector. • Strategic Acquisition: In January 2025, GEON Performance Solutions acquired Foster Corporation, a 36-year-old compounder of biomedical polymers, bioresorbable polymers, and PEEK and TPUs thermoplastic polyurethane elastomers. This was GEON’s fourth acquisition in 2020 and is further consolidation of specialty polymer compounders serving the medical device sector. • Expansion of Distribution Networks: Foster Medical Compounds appoints Formerra as their North and South American distributor of medical compounds, post acquisition by GEON, in August 2025. This extends Formerra’s regional coverage for healthcare polymer distribution. Distribution partnerships enable manufacturing of biomedical polymers to serve OEM customers, without the need for the biomedical polymer manufacturer to build regional sales networks. • Neural Regeneration Scaffolds Acquisition: Toray Industries, in October 2025, acquired a neural regeneration scaffold company in Japan, to enhance its fiber, and neural regeneration scaffold solutions with biodegradable polymer technologies and scaffold solutions. The acquisitions of specialized regenerative medicine capabilities demonstrate the increased competition for neural scaffold technology. • Domestic Feedstock Manufacturing Investment: The first unit of Balrampur Chini Mills' Bioyug polylactic acid (PLA) manufacturing plant in Lakhimpur Kheri, India, was completed in February 2025, as part of its ₹2,880 crore integrated sugarcane to PLA value-chain project. This project aims to produce 80,000 tons per year of capacity. This project will reduce India's reliance on imported PLA feedstock, which is a key ingredient in biodegradable sutures and implants. • Opening of A Medical Applications Center: Evonik opened its largest medical device applications center in Shanghai and offers research, development and processing of bioresorbable medical device components For the Asian market. These regional applications centers will cut the development time of medical device components for customers who previously had to send their projects to be done in either Europe or the USA. This investment positioning indicates that biodegradable medical polymer suppliers will adopt a multi-pronged strategy of acquisition, distribution, and regional manufacturing investment. This will impact the implant and drug-delivery markets in the coming years. Strategic Growth Opportunities in the Biodegradable Medical Polymer Market New markets for biodegradable polymers projected for 2024 to 2026 extend beyond traditional surgical markets. Lucintel’s latest report identifies these markets as cardiovascular, neural, and combination device markets. Manufacturers of biodegradable polymers will move up market to more sophisticated, complex, and higher priced products as these markets grow. • Bioresorbable Cardiovascular Scaffolds: Determination of the safety profiles for vascular scaffolds made of polylactide compared to permanent metal stents in the long-term ABSORB IV trial brought interest back to biodegradable cardiovascular scaffolds and devices. The newer generations of scaffolds address the issue of target lesion failure. This is a complex, high-value area of the market that few polymer manufacturers can adequately serve. • Neural Tissue Regeneration Scaffolds: There has been great investment and interest to commercially develop neural tissue engineering scaffolds evidenced by large, established materials companies buying specialized biomedical scaffold companies. New opportunities for scaffold technology in neurology, a currently untapped market, have high value. • Combination Drug-Device Products: There is a significant focus on pharmaceutical polymers designed for sustained and controlled drug release integrated with structural implants. Drug delivery systems account for nearly 30% of anticipated applications in 2026. There will be a premium placed on combination products as sustained and controlled drug delivery systems are favored by the pharmaceutical industry. • Geographic Expansion Into Domestic Feedstock Production: Countries solely dependent on imported polylactic acid are starting to produce locally, the fastest growing segment of this market being bioresorbable polymers in India at an estimated CAGR of 19.1% through 2036. With a focus on the domestic production of medical-grade polymers, countries will grant preferential access to early manufacturing partners. • Aftermarket Compounding and Custom Formulation Services: Specialty compounders that offer custom medical polymer formulations and provide cleanroom processing and regulatory support are becoming the preferred partners for companies without the capability of materials science. This separation from the raw polymer sale creates a service layer that enables suppliers to retain a steady income from a particular development of a device rather than a one-time sale. Across these five paths, higher growth is found in technically advanced applications which use biodegradable polymers to combine with drugs, neural tissue or cardiovascular tissue rather than just basic absorbable sutures. Suppliers with the capability of producing cardiovascular and neural scaffolds will be able to meet customer demands not fulfilled by bulk polymer producers. Biodegradable Medical Polymer Market Drivers and Challenges Although safety concerns about devices and rising material costs may discourage broader use of biodegradable materials, higher adoption of more absorbable implants and the growing interest in controlled-release drug delivery systems are expected to help drive biodegradable polymers' growth between now and 2026, according to a recent Lucintel report. Drivers • Absorbable Implants: The use of absorbable implants is predicted to increase greatly in the coming years. Because surgeons are now favoring implants that avoid the need for follow-up surgery to remove the implants, demand for implants will grow in a variety of specialties of surgery. Polylactic acid is estimated to comprise 35% of the global market by 2026. • Drug Delivery Systems: 2026 is expected to see a 30% market share for controlled release drug delivery systems as a result of the pharmaceutical industry's focus on local release rather than systemic release. This focus will drive polymer-based combined drug delivery systems. • Improved Manufacturing Process: The shift to injection molding has driven a 40% increase in the use of biodegradable polymers, mainly due to cost efficiency. continued improvement in manufacturing will result in a larger market service for biodegradable polymers. • Investments in Regional Supply Chain: The manufacturing of polylactic acid is increasing in countries previously dependent upon import. India's bioresorbable polymer segment is expected to have the fastest growth at 19.1% CAGR by 2036. Regional supply chain investments will allow manufacturing of biodegradable polymers to be more widely distributed to lower concentrated regions. • Fiber-Based Wound Care Applications: Fibers are estimated to encompass a major 38% share of biodegradable polymer forms by 2026. The increasing demand for surgical sutures and wound care drives fiber-based absorbable products. With the increasing volume of minimally invasive surgeries, fiber-based absorbable products will continue to anchor the steady and high volume baseline demand. Challenges • High Cost Materials: Biodegradable polymers like PLA cost approximately twice as much as traditional materials in some markets resulting in limited adoption by cost-conscious device manufacturers and healthcare systems. • Device Safety and Target Lesion Failure Risk: There are slightly higher target lesion failure rates shown in long-term studies of bioresorbable vascular scaffolds compared to metallic stents, and consequently, patient selection is of critical importance to minimize complications. • Certification and Compliance Complexity: ISO 13485 certification and cleanroom manufacturing add barriers for smaller compounders to enter the medical-grade biodegradable polymer production. Striking the right balance in these areas will distinguish winners from losers. Suppliers offering cost effective compliance and safety with regional supply diversification will win the decade long race against competitors still charging premium prices and unresolved performance concerns. List of Biodegradable Medical Polymer Market Companies Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies biodegradable medical polymer market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the biodegradable medical polymer market companies profiled in this report include- • Evonik Industries AG • Corbion N.V. • Mitsui Chemicals Inc. • Poly Medicure Limited • KLS Martin SE & Co. KG • BASF SE • NatureWorks LLC • Arkema SA • Eastman Chemical Company • Foster LLC Biodegradable Medical Polymer Market by Segment The study includes a forecast for the global biodegradable medical polymer market by material type, product form, application, and region. Biodegradable Medical Polymer Market by Material Type [Value ($B) from 2019 to 2035]: • Ceramic Matrix Composites • Oxide Ceramics • Non-Oxide Ceramics • Advanced Porous Ceramics Biodegradable Medical Polymer Market by Product Form [Value ($B) from 2019 to 2035]: • Powder • Tiles • Coatings • Fibers • Bulk Biodegradable Medical Polymer Market by Application [Value ($B) from 2019 to 2035]: • Drug Delivery • Implants • Sutures • Others Biodegradable Medical Polymer Market by Region [Value ($B) from 2019 to 2035]: • North America • Europe • Asia Pacific • The Rest of the World Country Wise Outlook for the Biodegradable Medical Polymer Market Improvement of bioresorbable implants and drug-delivery polymer technology will continue through 2026 as manufacturers produce more while new regulations in major markets are confirmed. According to Lucintel, new capacities for building absorbable medical materials supply chains will grow significantly in the coming years. • The United States: Data from Abbott's ABSORB IV trial publication in 2023 and references in 2025 literature, support long term safety of polylactide-based bioresorbable vascular scaffolds compared to metal stents. Most US device manufacturers are at the forefront of next generation resorbable cardiovascular technology due to continuous research on 3D Printing of PLLA-based scaffolds • China: Evonik's bioresorbable medical devices semifinished components opened its processing center in Shanghai. This allows China to strengthen its manufacturing and innovation services across Asia for biodegradable polymers. • Germany: Evonik continued building its RESOMER bioresorbable polymer platform citing longer safety studies of its poly-lactide-glycolide copolymer polymer that supports greater safety and efficacy in use cases where sutures, orthopedics, and drug delivery are combined. Continued investments across its Darmstadt and Birmingham, Alabama facilities strengthen Germany's position as a primary source of GMP-grade bioresorbable medical polymers. • India: Balrampur Chini Mills established the first unit of its Bioyug polylactic acid biopolymer plant in Lakhimpur Kheri, Uttar Pradesh, in February 2025, as part of its ₹2,880 crore sugarcane to PLA integrated project targeting 80,000 tonnes of annual capacity. This plant is the first major PLA production facility in India, addressing the country's need for biodegradable medical-grade polymer feedstock. • Japan: Toray Industries' acquisition of a Japanese biomedical scaffolds startup in October 2025 further augments its fibers and scaffolds for neural tissue regeneration built on biodegradable polymer technology. This acquisition adds Japanese materials companies to the next generation of resorbable scaffold technology for regenerative medicine. Features of the Global Biodegradable Medical Polymer Market Market Size Estimates: biodegradable medical polymer market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions. Segmentation Analysis: biodegradable medical polymer market size by material type, product form, application, and region in terms of value ($B). Regional Analysis: biodegradable medical polymer market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different material types, product forms, applications, and regions for the biodegradable medical polymer market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the biodegradable medical polymer market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model. If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more. This report answers following 11 key questions: Q.1. What are some of the most promising, high-growth opportunities for the biodegradable medical polymer market by material type (ceramic matrix composites, oxide ceramics, non-oxide ceramics, and advanced porous ceramics), product form (powder, tiles, coatings, fibers, and bulk), application (drug delivery, implants, sutures, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)? Q.2. Which segments will grow at a faster pace and why? Q.3. Which region will grow at a faster pace and why? Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market? Q.5. What are the business risks and competitive threats in this market? Q.6. What are the emerging trends in this market and the reasons behind them? Q.7. What are some of the changing demands of customers in the market? Q.8. What are the new developments in the market? Which companies are leading these developments? Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth? Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution? Q.11. What M&A activity has occurred in the last 6 years and what has its impact been on the industry?